Evaxion Biotech
Using cutting-edge immunology, bioinformatics, and machine learning methods, Evaxion Biotech is discovering and developing 'best in class’ vaccines for infectious diseases and cancer at an unprecedented rate. We have constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, PIONEER and EDEN. Using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. EDEN enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while PIONEER has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them.
Immunoinformatics Immunotherapy Antigen Discovery Bioinformatics
Technologies
AI Companies (Drug Discovery)Posts Mentioning This Company
R&D Platform
We are an AI-immunology platform company using our proprietary artificial intelligence technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop unique immunotherapies for patients.
Pipelines
EVX-01/-02
Our unique pipeline of immunotherapies addresses two of the biggest unmet medical needs worldwide – cancer and infectious diseases.
With a primary focus on discovery and early development, we are building on a simple and scalable business model with manageable risk. We intend to expand our current pipeline both within cancer and infectious diseases, and into other disease areas as we continue to explore new frontiers in AI-immunology.
The predictive power of our AI platforms rely our ability to process and interpret vast amounts of data, a process known as computational immunology. Using our in silico AI models, we are able to transform such data into advanced algorithms that we believe can accurately predict cellular interactions within the immune system and identify the right targets that will stimulate a relevant response. To translate our predictions into product candidates, we test multiple delivery modalities and move the most promising forward. This process allows us to discover unique drug candidates and to move them into the clinic without expending time and resources on clinical development of candidates that may ultimately fail to produce a therapeutic or prophylactic response.
EVX-03/-B1
Our unique pipeline of immunotherapies addresses two of the biggest unmet medical needs worldwide – cancer and infectious diseases.
With a primary focus on discovery and early development, we are building on a simple and scalable business model with manageable risk. We intend to expand our current pipeline both within cancer and infectious diseases, and into other disease areas as we continue to explore new frontiers in AI-immunology.
The predictive power of our AI platforms rely our ability to process and interpret vast amounts of data, a process known as computational immunology. Using our in silico AI models, we are able to transform such data into advanced algorithms that we believe can accurately predict cellular interactions within the immune system and identify the right targets that will stimulate a relevant response. To translate our predictions into product candidates, we test multiple delivery modalities and move the most promising forward. This process allows us to discover unique drug candidates and to move them into the clinic without expending time and resources on clinical development of candidates that may ultimately fail to produce a therapeutic or prophylactic response.
Products
Services
No services posted yet
